sb-258719 sb-258719 sb-258719 is a drug developed by glaxosmithkline which acts as a selective 5-ht7 receptor partial inverse agonist, and was the first such ligand identified for 5-ht7. its use in research has mainly been in demonstrating the potential use for 5-ht7 agonists as potential novel analgesics, due to the ability of sb-258719 to block the analgesic effects of a variety of 5-ht7 agonists across several different testing models. sb-258719identifiers iupac name (1r)-3,n-dimethyl-n-benzenesulfonamide cas number195199-95-2 npubchem cid5312148iuphar/bps281chemspider4471578 ychemblchembl12264 ychemical and physical dataformulac18h32n2o2smolar mass340.53 g·mol−13d model (jsmol)interactive image smiles c1ccc(c)cc1s(=o)(=o)n(c)c(c)ccn(cc2)ccc2c inchi inchi=1s/c18h30n2o2s/c1-15-8-11-20(12-9-15)13-10-17(3)19(4)23(21,22)18-7-5-6-16(2)14-18/h5-7,14-15,17h,8-13h2,1-4h3/t17-/m1/s1 ykey:agvnhdntfyhznl-qgzvfwflsa-n y ny (what is this?) (verify)